Organized by AMA-1 dose and Adjuvant Group, AEs solicited post immunization with highest grade reported. Reported by percentage experiencing AE, with percent experiencing Grade 3 in parentheses. Imm =

NIAID Data Ecosystem30

Adverse Event Dataset in Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 days) with Suspected or Complicated Intra-abdominal Infections

儿科临床药理学

HIV药物安全性监测

Timing and description of adverse events Study Description An open-label, multiple-dose study to determine the safety, tolerability, and pharmacokinetics of meropenem in preterm and term infants less

NIAID Data Ecosystem20

Summary of treatment-emergent adverse events.

资源简介：

相关数据集